Business Wire

Dole Advances Public-Private Partnerships to Expand Access to Essential Services for Agricultural Workers

2.6.2025 12:00:00 CEST | Business Wire | Press Release

Share

Dole (NYSE: DOLE) today announced the signing of new public-private agreements to advance its award-winning Information and Wellbeing Centers (IWCs), a workplace-based initiative pioneered by Dole designed to deliver vital public and private services directly to the workplace, improving quality of life for agricultural workers in Costa Rica’s rural areas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250602935679/en/

A panel discussion was held to discuss Public-Private Partnerships among business representatives and public organizations, including the CCSS (Costa Rican Social Security System) Financial Director, Gustavo Picado (second from left).

The announcement was made during the forum “Information and Wellbeing Centers: Public-Private Partnerships that Improve Lives,” hosted by Dole Fresh Fruit. During the event, Dole signed memorandums of understanding with two key national institutions—Caja Costarricense de Seguro Social (CCSS) and Banco Popular—further strengthening its commitment to inclusive development and equitable service access.

Launched in 2020, Dole’s IWC model has redefined how rural workers access healthcare, social security, education, and financial tools. By integrating these essential services directly into the workplace, IWCs eliminate major barriers such as distance, cost, and time. Currently, IWCs directly benefit over 3,300 individuals across four of Dole’s pineapple farms: Santa Fe, El Bosque, La Virgen, and Muelle, thanks to the collaboration of 38 public and private sector partners.

The new agreements with CCSS and Banco Popular—two pillars of Costa Rica’s public infrastructure—signal an expansion of the IWC network:

  • CCSS (Caja Costarricense de Seguro Social): As Costa Rica’s universal public healthcare and social insurance provider, CCSS plays a central role in delivering medical and social protection across the country.
  • Banco Popular: A state-owned bank with a social mission focused on financial inclusion and community development, serves working populations and grassroots enterprises across the country.

By formalizing their engagement, these institutions have committed to deepening their participation in the IWC network, advancing broader access to equitable solutions that uphold citizens’ rights and promote long-term well-being.

“This is a concrete example of how public-private partnerships can close gaps and generate real well-being,” said Rudy Amador, Regional Vice President of Social Responsibility, Sustainability, and Communications at Dole Fresh Fruit. “Inter-institutional coordination has been key to making the Information and Wellbeing Centers a powerful driver of inclusion.”

The forum convened national government leaders, business executives and international institutions to reflect on the success and scalability of the IWC model. The Aliarse Foundation, a Costa Rican NGO specializing in cross-sector partnerships, presented a case study during the event, followed by a panel discussion highlighting the social and economic benefits of collaborative development models.

In 2022, the IWC program received the Grand Prize for Social Responsibility in Action from the Costa Rican-American Chamber of Commerce (AMCHAM), recognizing its innovation and measurable impact.

To date, the IWC program has reached 14,947 individuals, with continued expansion planned for the years ahead. The initiative is increasingly recognized as a replicable blueprint for sustainable development.

The event concluded with a collective call to action: when the public sector, private enterprise, and civil society work together with intention, the result is a more just and connected society—one where access to essential services is not a privilege, but a right realized.

About Dole Food Company

Dole Food Company, part of Dole plc, is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education. For more information, please visit www.dole.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250602935679/en/

Contacts

Media Contact:
William Goldfield
818-292-0548
william.goldfield@dole.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release

Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye